Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other structural heart procedures.

Latest News

Share this


Venus Medtech Announces Agreement to Acquire Keystone Heart, LTD

Merger Establishes US and EMEA Presence for the Preeminent Chinese Structural Heart Company HANGZHOU, China and CAESAREA, Israel and TAMPA, Florida, Sept. 25, 2018 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc., the preeminent Chinese transcatheter heart valve company, today announced it has signed an agreement to acquire Keystone Heart Ltd., a privately-held medical device company...


REFLECT Clinical Update with TriGUARD3

Tamim Nazif Conclusions: TriGUARD 3 offers complete 3 vessel cerebral embolic protection for TAVR Specific design improvements optimize safety, efficacy generalizability, and ease of use of cerebral protection REFLECT Trial phase 2 is underway and expected to complete enrollment in early 2019 High rate of anatomic...


Current Cerebral Embolic Protection Landscape

Keystone Heart TriGUARD Data Review Jeffrey Moses Conclusions: Overt and Covert stroke are significant complications of TAVR which may be of greater consequence as we move in to lower risk, younger populations The weight of evidence indicates that CEP reduces these events By covering al 3 cerebral...


Join Keystone Heart at TCT2018

We invite you to explore and discuss with world-renown physicians the importance of complete cerebral embolic protection with TAVR. Please join us for the Keystone Heart Lunch Symposium during TCT 2018where we will share current research on cerebral embolic debris during TAVR, progress of the...


TCT2018 Plans

Keystone Heart is excited to share with you our plans during TCT2018. TCT is the largest interventional cardiovascular medicine meeting focusing on education in the field of interventional and vascular medicine. This year it's in sunny San Diego, CA! In the spirit of TCT, Keystone Heart...